Algernon Pharmaceuticals (XTER:BTI) LT-Debt-to-Total-Asset : 0.00 (As of Feb. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Algernon Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Feb. 2024 was 0.00.

Algernon Pharmaceuticals's long-term debt to total assets ratio stayed the same from Feb. 2023 (0.00) to Feb. 2024 (0.00).

Algernon Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Algernon Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals LT-Debt-to-Total-Asset Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Algernon Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Algernon Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Algernon Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2023 is calculated as

LT Debt to Total Assets (A: Aug. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Aug. 2023 )	/	Total Assets (A: Aug. 2023 )
	=	0	/	2.853
	=

Algernon Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2024 is calculated as

LT Debt to Total Assets (Q: Feb. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Feb. 2024 )	/	Total Assets (Q: Feb. 2024 )
	=	0	/	2.715
	=

Algernon Pharmaceuticals (XTER:BTI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Algernon Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (XTER:BTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XTER:BTI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.